ClinicalTrials.gg
RecruitingNCT07739316RECORDIIUpdated Nov 4, 2026

Systematic Ambulatory ECG Monitoring Following TAVI

An interventional study of Ambulatory ECG monitoring in Aortic Stenosis and Conduction Disturbances, sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
754
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Aortic Valve Stenosis with a site in Canada — 23 open to participants now, 36 under way, 1 of them phase 3. Aortic Valve Stenosis · Canada.

Planned enrollment
22nd of 60
754 · median 300
Started
2026
with 2 others
No phase
49 of 87
11 open now
Primary completion
2028-12
later than 26 of 35 live
Registered
86th of 87
by date
Lead sponsor
5 of 87
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Among the 87 studies in Aortic Valve Stenosis with a site in Canada, this one is the 22nd largest by planned enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2026, is one of 49 with no phase, reaches primary completion later than 26 of the 35 other live ones, and was the 86th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

23 of the 87 studies in Aortic Valve Stenosis with a site in Canada are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Aortic Valve Stenosis with a site in Canada, or all of them as a file.
02

Study summary

This multicenter, prospective, randomized superiority trial will evaluate whether systematic 14-day ambulatory ECG monitoring following hospital discharge after transcatheter aortic valve implantation (TAVI) reduces the risk of sudden death, symptomatic arrhythmic events, or stroke within 1 year compared with standard post-discharge care. Patients undergoing successful TAVI without permanent pacemaker implantation and presenting with at least one ECG conduction abnormality at hospital discharge will be randomized to receive either ambulatory ECG monitoring or standard follow-up. All participants will undergo routine clinical follow-up at 30 days and 1 year after TAVI.

Read the detailed description

Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis. Despite advances in transcatheter heart valve technology and procedural techniques, conduction disturbances remain among the most frequent complications following TAVI. High-grade atrioventricular block, complete heart block, and new-onset bundle branch block may occur after the procedure and can lead to delayed permanent pacemaker implantation or life-threatening arrhythmic events. The increasing adoption of minimalist TAVI pathways with hospital discharge within 24-72 hours raises concerns that clinically significant arrhythmias may develop after discharge and remain undetected.

Ambulatory electrocardiographic (ECG) monitoring provides continuous rhythm surveillance during daily activities and enables the early detection of both symptomatic and asymptomatic bradyarrhythmias and tachyarrhythmias. Previous observational studies have demonstrated that clinically significant bradyarrhythmias occur in approximately 5-10% of patients during the first weeks after TAVI, particularly among those with baseline or new-onset conduction abnormalities. Ambulatory ECG monitoring has also identified previously unrecognized atrial fibrillation, allowing timely initiation of anticoagulation therapy in patients at high risk of thromboembolic events.

Although several prospective studies have evaluated ambulatory ECG monitoring after TAVI, most have been observational and were designed primarily to describe the incidence of post-procedural arrhythmias rather than to assess their impact on clinical outcomes. Preliminary evidence from the RECORD pilot study suggested that systematic ambulatory ECG monitoring after hospital discharge was associated with earlier identification and treatment of clinically significant arrhythmias and a reduction in the composite of sudden death, symptomatic arrhythmic events, and stroke during 1-year follow-up, with the greatest benefit observed among patients with conduction abnormalities at hospital discharge.

This randomized trial has been designed to provide definitive evidence regarding the clinical value of systematic ambulatory ECG monitoring after TAVI in patients at increased risk of post-procedural conduction disturbances. The study will evaluate whether early detection and management of clinically significant arrhythmias can improve clinical outcomes during the year following the procedure.

03

Conditions studied

  • Aortic Stenosis
  • Conduction Disturbances

Keywords

  • TAVI
  • Ambulatory Electrocardiographic Monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Successful TAVI procedure.
  • Hospitalization discharge ≤72 hrs following the TAVI procedure.
  • Presence of at least 1 abnormality at hospital discharge (QRS ≥120 ms OR PR ≥200 ms)

Exclusion criteria

Exclusion Criteria:

  • Pacemaker implantation (pre- TAVI or during hospitalization after the procedure).
  • TAVI valve-in-valve procedure
  • Any complication or logistic reason precluding hospital discharge ≤72 hrs following the TAVI procedure.
  • Impossibility to obtain signed .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
754 participants (estimated)

Study arms

  • Experimental
    Ambulatory ECG monitoring

    Participants will undergo ambulatory ECG monitoring at hospital discharge following TAVI. Continuous ECG monitoring will be performed for 14 days using an ambulatory ECG monitoring device. Clinically significant bradyarrhythmias or tachyarrhythmias detected during monitoring will be reviewed and managed according to clinical practice, including appropriate therapeutic interventions when indicated.

    Device: Ambulatory ECG monitoring

  • No intervention
    Standard care (no ambulatory ECG monitoring device).

    Participants will receive standard post-TAVI care without systematic ambulatory ECG monitoring at hospital discharge. Clinical follow-up will be performed according to routine practice.

Interventions

  • DeviceAmbulatory ECG monitoring

    Participants randomized to the intervention arm will undergo systematic ambulatory ECG monitoring at hospital discharge following the TAVI procedure. A wearable ambulatory ECG monitoring device will be applied for continuous rhythm monitoring during a 14-day period. The device will allow detection of clinically significant bradyarrhythmias and tachyarrhythmias. Detected arrhythmic events will be reviewed by the study team, and appropriate clinical management, including further evaluation or therapeutic intervention, will be performed according to the nature of the detected abnormality and standard clinical practice.

06

What researchers measure

Primary outcomes

  1. Rate of the combined endpoint (sudden death, symptomatic arrhythmias or stroke)

    Composite endpoint including sudden death, symptomatic arrhythmias, or stroke.

    Time frame: Within the year following the TAVI procedure

Secondary outcomes

  1. Incidence of sudden death

    Sudden death

    Time frame: 1 year after TAVI

  2. Incidence of symptomatic arrhythmias

    All symptomatic arrhythmias events

    Time frame: 1 year after TAVI

  3. Incidence of stroke

    All stroke events

    Time frame: 1 year after TAVI

  4. Incidence of PPI

    Number of patients with PPI

    Time frame: 30 days after TAVI

  5. Incidence of PPI

    Number of patients with PPI

    Time frame: 1 year after TAVI

  6. Incidence of the combined endpoint (sudden death, symptomatic arrhythmias or stroke) at 30 days

    Composite endpoint including sudden death, symptomatic arrhythmias, or stroke.

    Time frame: 30 days after TAVI

  7. Incidence of sudden death

    Sudden death

    Time frame: 30 days after TAVI

  8. Incidence of symptomatic arrhytmias

    All symptomatic arrhythmias events

    Time frame: 30 days after TAVI

  9. Incidence of stroke

    All stroke events

    Time frame: 30 days after TAVI

  10. Incidence of the combined endpoint (sudden death, symptomatic arrhythmias, stroke) according to patient sex

    Composite endpoint including sudden death, symptomatic arrhythmias, or stroke, analyzed according to patient sex.

    Time frame: 1 year after TAVI

  11. Incidence of the combined endpoint of sudden death, symptomatic arrhythmias, or stroke) according to ECG abnormalities

    Composite endpoint including sudden death, symptomatic arrhythmias, or stroke, analyzed according to ECG abnormality status (pre-existing versus new-onset after TAVI).

    Time frame: 1 year after TAVI

  12. Incidence of the combined endpoint according to baseline ECG abnormality type

    Composite endpoint (sudden death, symptomatic arrhythmias, or stroke) analyzed according to the type of ECG abnormality present before TAVI.

    Time frame: 1 year after TAVI

  13. Incidence of sudden death according to baseline ECG abnormality type

    Sudden death analyzed according to the type of ECG abnormality present before TAVI.

    Time frame: 1 year after TAVI

  14. Incidence of symptomatic arrhythmias according to baseline ECG abnormality type

    Symptomatic arrhythmias according to the type of ECG abnormality present before TAVI.

    Time frame: 1 year after TAVI

  15. Incidence of stroke according to baseline ECG abnormality type

    Stroke according to the type of ECG abnormality present before TAVI.

    Time frame: 1 year after TAVI

  16. Incidence of the combined endpoint according to discharge ECG abnormality type

    Composite endpoint (sudden death, symptomatic arrhythmias, or stroke) according to the type of ECG abnormality present at hospital discharge.

    Time frame: 1 year after TAVI

  17. Incidence of sudden death according to discharge ECG abnormality type

    Sudden death according to the type of ECG abnormality present at hospital discharge.

    Time frame: 1 year after TAVI

  18. Incidence of symptomatic arrhythmias according to discharge ECG abnormality type

    Symptomatic arrhythmias according to the type of ECG abnormality present at hospital discharge.

    Time frame: 1 year after TAVI

  19. Incidence of stroke according to discharge ECG abnormality type

    Stroke according to the type of ECG abnormality present at hospital discharge.

    Time frame: 1 year after TAVI

  20. Change in quality of life

    Quality of life assessed using the EQ-5D-5L questionnaire.

    Time frame: Baseline to 1 year after TAVI

  21. Percentage of ventricular pacing

    Ventricular pacing burden in participants with permanent pacemakers.

    Time frame: 1 year after TAVI

  22. Incidence of all-cause mortality

    All-cause mortality

    Time frame: 30 days after TAVI

  23. Incidence of cardiovascular mortality

    Cardiovascular mortality

    Time frame: 30 days after TAVI

  24. Incidence of all-cause mortality

    All cause mortality

    Time frame: 1 year after TAVI

  25. Incidence of cardiovasculare mortality

    Cardiovascular mortality

    Time frame: 1 year after TAVI

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ; ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015 Nov 1;36(41):2793-2867. doi: 10.1093/eurheartj/ehv316. Epub 2015 Aug 29. No abstract available. PubMed 26320108 ↗
  • Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e210-e271. doi: 10.1161/CIR.0000000000000548. No abstract available. PubMed 29084733 ↗
  • Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS. Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score. Circulation. 2019 Nov 12;140(20):1639-1646. doi: 10.1161/CIRCULATIONAHA.119.041303. Epub 2019 Sep 30. PubMed 31564126 ↗
  • Writing Committee Members; Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024 Jan 2;83(1):109-279. doi: 10.1016/j.jacc.2023.08.017. Epub 2023 Nov 30. PubMed 38043043 ↗
  • Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM, Joglar JA, Kim RJ, Lee R, Marine JE, McLeod CJ, Oken KR, Patton KK, Pellegrini CN, Selzman KA, Thompson A, Varosy PD. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019 Aug 20;74(7):e51-e156. doi: 10.1016/j.jacc.2018.10.044. Epub 2018 Nov 6. No abstract available. PubMed 30412709 ↗
  • Nuche J, Soliman F, Chavarria J, Okoh AK, Alvarado Mora H, Nault I, Natarajan MK, Russo M, Philippon F, Rodes-Cabau J. New-onset atrial fibrillation detected by ambulatory ECG monitoring after transcatheter aortic valve implantation. EuroIntervention. 2024 May 10;20(9):591-601. doi: 10.4244/EIJ-D-23-01014. PubMed 38726722 ↗
  • Muntane-Carol G, Urena M, Nombela-Franco L, Amat-Santos I, Kleiman N, Munoz-Garcia A, Atienza F, Serra V, Deyell MW, Veiga-Fernandez G, Masson JB, Canadas-Godoy V, Himbert D, Castrodeza J, Elizaga J, Francisco Pascual J, Webb JG, de la Torre Hernandez JM, Asmarats L, Pelletier-Beaumont E, Philippon F, Rodes-Cabau J. Arrhythmic burden in patients with new-onset persistent left bundle branch block after transcatheter aortic valve replacement: 2-year results of the MARE study. Europace. 2021 Feb 5;23(2):254-263. doi: 10.1093/europace/euaa213. PubMed 33083813 ↗
  • Fischer Q, Urena M, Muntane-Carol G, Alperi A, Nombela-Franco L, Veiga G, Regueiro A, Suc G, Romaguera R, Avanzas P, Tirado-Conte G, de la Torre Hernandez JM, Cepas-Guillen P, Cote M, Philippon F, Rodes-Cabau J. Same-Day Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2025 Jul 28;18(14):1776-1785. doi: 10.1016/j.jcin.2025.05.041. PubMed 40738576 ↗
  • Fischer Q, Nombela-Franco L, Muntane-Carol G, Veiga G, Regueiro A, Nazif T, Serra V, Asmarats L, Ribeiro HB, Latib A, Poulin A, Cheema AN, Jimenez-Quevedo P, Gomez-Hospital JA, Gil Ongay A, Ruberti A, Arzamendi D, Brener M, Calabuig A, Scotti A, Gelain MAS, Labinaz M, Cepas-Guillen P, Cote M, Del Portillo JH, Philippon F, Rodes-Cabau J. Risk of delayed atrioventricular block in patients without procedural conduction disturbances during transcatheter aortic valve replacement. Heart Rhythm. 2026 Apr;23(4):955-962. doi: 10.1016/j.hrthm.2025.04.017. Epub 2025 Apr 14. PubMed 40239910 ↗
  • Natarajan MK, Sheth TN, Wijeysundera HC, Chavarria J, Rodes-Cabau J, Velianou JL, Radhakrishnan S, Newman T, Smith A, Wong JA, Schwalm JD, Duong M, Mian RI, Bishop MG, Healey JS. Remote ECG monitoring to reduce complications following transcatheter aortic valve implantations: the Redirect TAVI study. Europace. 2022 Oct 13;24(9):1475-1483. doi: 10.1093/europace/euac042. PubMed 35699482 ↗
  • Muntane-Carol G, Okoh AK, Chen C, Nault I, Kassotis J, Mohammadi S, Coromilas J, Lee LY, Alperi A, Philippon F, Russo MJ, Rodes-Cabau J. Ambulatory Electrocardiographic Monitoring Following Minimalist Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2021 Dec 27;14(24):2711-2722. doi: 10.1016/j.jcin.2021.08.039. PubMed 34949396 ↗
  • Winter JL, Healey JS, Sheth TN, Velianou JL, Schwalm JD, Smith A, Reza S, Natarajan MK. Remote Ambulatory Cardiac Monitoring Before and After Transcatheter Aortic Valve Replacement. CJC Open. 2020 Apr 25;2(5):416-419. doi: 10.1016/j.cjco.2020.04.006. eCollection 2020 Sep. PubMed 32995727 ↗
  • Skaf M, Makki N, Coressel A, Matre N, O'Neill S, Boudoulas K, Rushing G, Lilly SM. Rhythm Disturbances After Transcatheter Aortic Valve Replacement: A Strategy of Surveillance. Cardiovasc Revasc Med. 2020 Apr;21(4):475-478. doi: 10.1016/j.carrev.2019.07.017. Epub 2019 Jul 30. No abstract available. PubMed 31431323 ↗
  • Tian Y, Padmanabhan D, McLeod CJ, Zhang P, Xiao P, Sandhu GS, Greason KL, Gulati R, Nkomo VT, Rihal CS, Polk LE, Sanvick C, Liu XP, Friedman PA, Cha YM. Utility of 30-Day Continuous Ambulatory Monitoring to Identify Patients With Delayed Occurrence of Atrioventricular Block After Transcatheter Aortic Valve Replacement. Circ Cardiovasc Interv. 2019 Dec;12(12):e007635. doi: 10.1161/CIRCINTERVENTIONS.118.007635. Epub 2019 Dec 13. PubMed 31833417 ↗
  • Ream K, Sandhu A, Valle J, Weber R, Kaizer A, Wiktor DM, Borne RT, Tumolo AZ, Kunkel M, Zipse MM, Schuller J, Tompkins C, Rosenberg M, Nguyen DT, Cleveland JC Jr, Fullerton D, Carroll JD, Messenger J, Sauer WH, Aleong RG, Tzou WS. Ambulatory Rhythm Monitoring to Detect Late High-Grade Atrioventricular Block Following Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2019 May 28;73(20):2538-2547. doi: 10.1016/j.jacc.2019.02.068. PubMed 31118148 ↗
  • Rodes-Cabau J, Urena M, Nombela-Franco L, Amat-Santos I, Kleiman N, Munoz-Garcia A, Atienza F, Serra V, Deyell MW, Veiga-Fernandez G, Masson JB, Canadas-Godoy V, Himbert D, Castrodeza J, Elizaga J, Francisco Pascual J, Webb JG, de la Torre JM, Asmarats L, Pelletier-Beaumont E, Philippon F. Arrhythmic Burden as Determined by Ambulatory Continuous Cardiac Monitoring in Patients With New-Onset Persistent Left Bundle Branch Block Following Transcatheter Aortic Valve Replacement: The MARE Study. JACC Cardiovasc Interv. 2018 Aug 13;11(15):1495-1505. doi: 10.1016/j.jcin.2018.04.016. Epub 2018 Jul 18. PubMed 30031719 ↗
  • Jorgensen TH, Thyregod HG, Tarp JB, Svendsen JH, Sondergaard L. Temporal changes of new-onset atrial fibrillation in patients randomized to surgical or transcatheter aortic valve replacement. Int J Cardiol. 2017 May 1;234:16-21. doi: 10.1016/j.ijcard.2017.02.098. Epub 2017 Feb 24. PubMed 28258844 ↗
  • Steinberg JS, Varma N, Cygankiewicz I, Aziz P, Balsam P, Baranchuk A, Cantillon DJ, Dilaveris P, Dubner SJ, El-Sherif N, Krol J, Kurpesa M, La Rovere MT, Lobodzinski SS, Locati ET, Mittal S, Olshansky B, Piotrowicz E, Saxon L, Stone PH, Tereshchenko L, Turitto G, Wimmer NJ, Verrier RL, Zareba W, Piotrowicz R. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm. 2017 Jul;14(7):e55-e96. doi: 10.1016/j.hrthm.2017.03.038. Epub 2017 May 8. PubMed 28495301 ↗
  • Sana F, Isselbacher EM, Singh JP, Heist EK, Pathik B, Armoundas AA. Wearable Devices for Ambulatory Cardiac Monitoring: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Apr 7;75(13):1582-1592. doi: 10.1016/j.jacc.2020.01.046. PubMed 32241375 ↗
  • Muntane-Carol G, Urena M, Munoz-Garcia A, Padron R, Gutierrez E, Regueiro A, Serra V, Capretti G, Himbert D, Moris C, Sabate M, Garcia Del Blanco B, Ferreira-Neto AN, Cote M, Fischer Q, Couture T, Kalavrouziotis D, Rodes-Cabau J. Late Cerebrovascular Events Following Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2020 Apr 13;13(7):872-881. doi: 10.1016/j.jcin.2019.11.022. Epub 2020 Mar 11. PubMed 32171718 ↗
  • Nombela-Franco L, Webb JG, de Jaegere PP, Toggweiler S, Nuis RJ, Dager AE, Amat-Santos IJ, Cheung A, Ye J, Binder RK, van der Boon RM, Van Mieghem N, Benitez LM, Perez S, Lopez J, San Roman JA, Doyle D, Delarochelliere R, Urena M, Leipsic J, Dumont E, Rodes-Cabau J. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation. 2012 Dec 18;126(25):3041-53. doi: 10.1161/CIRCULATIONAHA.112.110981. Epub 2012 Nov 13. PubMed 23149669 ↗
  • Siontis GCM, Praz F, Lanz J, Vollenbroich R, Roten L, Stortecky S, Raber L, Windecker S, Pilgrim T. New-onset arrhythmias following transcatheter aortic valve implantation: a systematic review and meta-analysis. Heart. 2018 Jul;104(14):1208-1215. doi: 10.1136/heartjnl-2017-312310. Epub 2017 Dec 23. PubMed 29275399 ↗
  • Jorgensen TH, De Backer O, Gerds TA, Bieliauskas G, Svendsen JH, Sondergaard L. Immediate Post-Procedural 12-Lead Electrocardiography as Predictor of Late Conduction Defects After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2018 Aug 13;11(15):1509-1518. doi: 10.1016/j.jcin.2018.04.011. PubMed 30093055 ↗
  • Mangieri A, Lanzillo G, Bertoldi L, Jabbour RJ, Regazzoli D, Ancona MB, Tanaka A, Mitomo S, Garducci S, Montalto C, Pagnesi M, Giannini F, Giglio M, Montorfano M, Chieffo A, Rodes-Cabau J, Monaco F, Paglino G, Della Bella P, Colombo A, Latib A. Predictors of Advanced Conduction Disturbances Requiring a Late (>/=48 H) Permanent Pacemaker Following Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2018 Aug 13;11(15):1519-1526. doi: 10.1016/j.jcin.2018.06.014. PubMed 30093056 ↗
  • Kooistra NHM, van Mourik MS, Rodriguez-Olivares R, Maass AH, Nijenhuis VJ, van der Werf R, Ten Berg JM, Kraaijeveld AO, Baan J Jr, Voskuil M, Vis MM, Stella PR. Late onset of new conduction disturbances requiring permanent pacemaker implantation following TAVI. Heart. 2020 Aug;106(16):1244-1251. doi: 10.1136/heartjnl-2019-315967. Epub 2020 Jan 31. PubMed 32005676 ↗
  • Wood DA, Lauck SB, Cairns JA, Humphries KH, Cook R, Welsh R, Leipsic J, Genereux P, Moss R, Jue J, Blanke P, Cheung A, Ye J, Dvir D, Umedaly H, Klein R, Rondi K, Poulter R, Stub D, Barbanti M, Fahmy P, Htun N, Murdoch D, Prakash R, Barker M, Nickel K, Thakkar J, Sathananthan J, Tyrell B, Al-Qoofi F, Velianou JL, Natarajan MK, Wijeysundera HC, Radhakrishnan S, Horlick E, Osten M, Buller C, Peterson M, Asgar A, Palisaitis D, Masson JB, Kodali S, Nazif T, Thourani V, Babaliaros VC, Cohen DJ, Park JE, Leon MB, Webb JG. The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers: The 3M TAVR Study. JACC Cardiovasc Interv. 2019 Mar 11;12(5):459-469. doi: 10.1016/j.jcin.2018.12.020. PubMed 30846085 ↗
  • Rodes-Cabau J, Ellenbogen KA, Krahn AD, Latib A, Mack M, Mittal S, Muntane-Carol G, Nazif TM, Sondergaard L, Urena M, Windecker S, Philippon F. Management of Conduction Disturbances Associated With Transcatheter Aortic Valve Replacement: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019 Aug 27;74(8):1086-1106. doi: 10.1016/j.jacc.2019.07.014. PubMed 31439219 ↗
  • Nuche J, Ellenbogen KA, Mittal S, Windecker S, Benavent C, Philippon F, Rodes-Cabau J. Conduction Disturbances After Transcatheter Aortic Valve Replacement: An Update on Epidemiology, Preventive Strategies, and Management. JACC Cardiovasc Interv. 2024 Nov 25;17(22):2575-2595. doi: 10.1016/j.jcin.2024.07.032. PubMed 39603774 ↗

Individual participant data

Plan to share: Undecided — A decision regarding IPD sharing has not yet been made. Following study completion, requests for access to de-identified individual participant data may be considered by the sponsor on a case-by-case basis, subject to ethical, legal, and institutional requirements.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 26 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 31, 2026
StartActual
Oct 23, 2026was Aug 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
Institut universitaire de cardiologie et de pneumologie de Québec - UL is now Recruiting
Nov 4, 2026
Start date
Aug 2026→Oct 23, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    Institut universitaire de cardiologie et de pneumologie de Québec - UL is now Recruiting
    Start date Aug 2026→Oct 23, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07739316
Lead sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Responsible party
Josep Rodes-Cabau (Principal Investigator, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval) — Principal investigator
First posted
Jul 31, 2026
Start date
Oct 23, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Josep Rodes-Cabau, MD, PhD
Contact
josep.rodes-cabau@criucpq.ulaval.ca
14186568711
Emilie Pelletier Beaumont, MSc
Contact
emilie.pelletier-beaumont@criucpq.ulaval
4186568711 ext. 3929
Josep Rodes-Cabau, MSc
principal investigator · Fondation IUCPQ

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion